Compare AQB & FEED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AQB | FEED |
|---|---|---|
| Founded | 1991 | 2003 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.6M |
| IPO Year | 2017 | N/A |
| Metric | AQB | FEED |
|---|---|---|
| Price | $0.95 | $0.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.7K | ★ 571.5K |
| Earning Date | 05-14-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.66 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,472,659.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $0.72 |
| 52 Week High | $2.95 | $6.09 |
| Indicator | AQB | FEED |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 37.46 |
| Support Level | $0.86 | $0.84 |
| Resistance Level | $1.02 | $0.97 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 41.95 | 41.11 |
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.